Facilitating Access to Approved Medication
Get Access To Sunlenca 464 Mg Solution For Injection
Sunlenca 464 Mg Solution For Injection
- API: Idelalisib
- Packaging: Tablets
- Strength: 100 mg and 150 mg Tablets
What is Sunlenca 464 Mg Solution For Injection used for?
Idelalisib is a kinase inhibitor indicated for the treatment of patients with:
Relapsed chronic lymphocytic leukemia (CLL), in combination with rituximab, in patients for whom rituximab alone would be considered appropriate therapy due to other co-morbidities.
Note: (For Prescribing Information Approved Drugs, see)
- The Food and Drug Administration (FDA), USA.
- The European Medicines Agency (EMA).
All Trademarks and Brands that appear on website belong to their respective owners does not lay and claim on them we only provide Information. We are NOT ONLINE store and We do not sell Narcotics and Sedatives. Sunlenca 464 Mg Solution For Injection is a pharmaceutical drug To access this medicine, a prescription of your treating doctor is necessary.. Following Information meant for Wholesalers, Suppliers, Exporters, Doctors, Comparator Supplies, Hospitals, Generic, Brand, Corporate Sourcing, reseller, and Pharmacies.